Sugi Predict

Sugi Predict / Compounds / SCHEMBL5336869

SCHEMBL5336869

SCHEMBL5336869

CC1(C)OB(c2ccc(COC(N)=O)cc2)OC1(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F11 P03951 3/20 0.56
▸ LIPG Q9Y5X9 8/20 0.51
▸ LPL P06858 7/20 0.51
▸ F2 P00734 2/20 0.50
▸ PRSS1 P07477 2/20 0.50
▸ PRSS2 P07478 2/20 0.50
▸ PRSS3 P35030 2/20 0.50
▸ CA1 P00915 5/20 0.47
▸ CA2 P00918 5/20 0.47
▸ CA9 Q16790 5/20 0.47
▸ ESR2 Q92731 1/20 0.46
▸ CA12 O43570 1/20 0.43
▸ CA3 P07451 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ CA6 P23280 1/20 0.43
▸ CA5A P35218 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ CA5B Q9Y2D0 1/20 0.43
▸ KEAP1 Q14145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21383621 0.88 LIPG (0.54) F11LIPGLPLF2PRSS1
SCHEMBL21383623 0.86 LIPG (0.53) F11LIPGLPLF2PRSS1
SCHEMBL16256313 0.86 LIPG (0.53) F11LIPGLPLF2PRSS1
SCHEMBL16112518 0.85 LIPG (0.56) F11LIPGLPLF2PRSS1
SCHEMBL14707180 0.85 LIPG (0.51) F11LIPGLPLF2PRSS1
SCHEMBL17734240 0.84 LIPG (0.50) F11LIPGLPLF2PRSS1
SCHEMBL22871651 0.84 LIPG (0.54) F11LIPGLPLF2PRSS1
SCHEMBL28435024 0.84 F11 (0.38) F11LIPGLPLF2PRSS1
SCHEMBL5332795 0.83 LIPG (0.52) F11LIPGLPLF2PRSS1
SCHEMBL14709908 0.82 LIPG (0.49) F11LIPGLPLF2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
CN-116981675-A Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2023-10-31 — — CN disclosed
CN-116710430-A Methods and compounds for restoring mutant p53 function 皮姆维制药公司 2023-09-05 — — CN disclosed
CN-111698989-B Heterocyclic substituted pyridine derivatives as antifungal agents 安普利克斯制药公司 2023-08-01 — — CN disclosed
CN-112608320-B Piperidine compound and preparation method and medical application thereof 中国药科大学 2023-03-17 — — CN disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
CN-113248449-B Aryl spiro-compound containing formamidine and preparation method and application thereof 中国药科大学 2022-09-23 — — CN disclosed
CN-113248449-A Aryl spiro-compound containing formamidine and preparation method and application thereof 中国药科大学 2021-08-13 — — CN disclosed
CN-112608320-A Piperidine compound and preparation method and medical application thereof 中国药科大学 2021-04-06 — — CN disclosed
CN-110546144-A Liver X Receptor (LXR) modulators PHENEX FXR GMBH 2019-12-06 — — CN disclosed
US-10377748-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2019-08-13 — — US disclosed
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-09-13 — — US disclosed
EP-3121288-A1 ELECTRONIC MEASUREMENTS OF MONOLAYERS FOLLOWING HOMOGENEOUS REACTIONS OF THEIR COMPONENTS Ohmx Corporation (US) 2017-01-25 — — EP disclosed
WO-2016025539-A1 ENZYME TRIGGERED REDOX ALTERING CHEMICAL ELIMINATION (-TRACE) ASSAY WITH MULTIPLEXING CAPABILITIES OHMX CORPORATION (US) 2016-02-18 — — WO disclosed
EP-2822559-A1 IMIDAZO [1, 2 - B]PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF Lexicon Pharmaceuticals, Inc. (US) 2015-01-14 — — EP disclosed
EP-2642291-A1 Enzyme triggered redox altering chemical elimination (E-trace) immunoassay Ohmx Corporation (US) 2013-09-25 — — EP disclosed
WO-2013134219-A1 IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF LEXICON PHARMACEUTICALS, INC. (US) 2013-09-12 — — WO disclosed
WO-2013067349-A1 NOVEL CHEMISTRY USED IN BIOSENSORS OHMX CORPORATION (US) 2013-05-10 — — WO disclosed
WO-2007062459-A1 SELECTIVE KINASE INHIBITORS BASED ON PYRIDINE SCAFFOLD CYTOPIA RESEARCH PTY LTD (AU) 2007-06-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS F11 3706/4885LIPG 1641/4885LPL 664/4885
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS F11 3706/4885LIPG 1641/4885LPL 664/4885
US-10377748-B2 Hepatitis B core protein modulators HAVCR2, FABP1, MAVS F11 3706/4885LIPG 1641/4885LPL 664/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS F11 3706/4885LIPG 1641/4885LPL 664/4885
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS F11 3706/4885LIPG 1641/4885LPL 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.